Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial
Petra Langerbeins,Sandra Robrecht,Pascal Nieper,Paula Cramer,Moritz Fürstenau,Othman Al-Sawaf,Florian Simon,Anna-Maria Fink,Karl-Anton Kreuzer,Ursula Vehling-Kaiser,Eugen Tausch,Christof Schneider,Lothar Müller,Michael Josef Eckart,Rudolf Schlag,Werner Freier,Tobias Gaska,Christina Balser,Marcel Reiser,Martina Stauch,Mark-Oliver Zahn,Steffen Dörfel,Peter Staib,Timo Behlendorf,Manfred Hensel,Holger Hebart,Holger Klaproth,Andreas Block,Rüdiger Liersch,Ulrich Hauch,Bernhard Heinrich,Clemens-Martin Wendtner,Kirsten Fischer,Stephan Stilgenbauer,Barbara Eichhorst,Michael Hallek
DOI: https://doi.org/10.1200/jco.24.00975
IF: 45.3
2024-11-29
Journal of Clinical Oncology
Abstract:PURPOSE The CLL12 trial reassesses the watch-and-wait consensus for early-stage chronic lymphocytic leukemia (CLL) in the context of targeted therapies. METHODS The German CLL Study Group conducted a randomized, double-blind, placebo-controlled phase III trial with 363 patients with asymptomatic, treatment-naïve Binet stage A CLL at increased risk of progression to receive ibrutinib (n = 182) at a daily dose of 420 mg or placebo (n = 181). Additionally, 152 low-risk patients were allocated to the watch-and-wait group. The final analysis included event-free survival, progression-free survival, time to next treatment, overall survival, and safety assessments. RESULTS Ibrutinib significantly delayed progression to symptomatic disease ( P < .001; hazard ratio, 0.276 [95% CI, 0.188 to 0.407]), but no survival benefit was observed with 26 death cases ( P = .562) at a median observation time of 69.3 months. Five-year survival rates were excellent: 93.3% (95% CI, 89.3 to 97.3) in the ibrutinib group, 93.6% (95% CI, 89.5 to 97.7) in the placebo group, and 97.9% (95% CI, 95.6 to 100) in the watch-and-wait cohort. Estimated 10-year survival rates from diagnosis were 86.5% (95% CI, 78.7 to 94.3, placebo), 89.8% (95% CI, 83.3 to 96.3, ibrutinib), and 95.3% (95% CI, 91.1 to 99.4, watch and wait). In the ibrutinib group, one of 12 deaths was CLL-associated, compared with four of 14 fatal cases of CLL progression or Richter transformation in the placebo group. Adverse and serious adverse events occurred in 99.4% and 60% of both treatment groups, respectively. The safety profile indicated increased cardiovascular toxicity in the ibrutinib group. CONCLUSION Ibrutinib treatment in early-stage CLL delayed disease progression compared with placebo. However, with the given observation time and few deaths, no survival benefit was demonstrated. In the era of targeted therapies, watch and wait remains the standard of care irrespective of risk factors.
oncology